促动力药治疗胃食管反流病的循证评价和进展  

Evidence-based Evaluation and Advances of Prokinetic Agents in Treatment of Gastroesophageal Reflux Disease

作　　者：丁黎葭[1] 陈世耀[1] 

机构地区：[1]复旦大学附属中山医院消化科,200032

出　　处：《胃肠病学》2009年第10期633-636,共4页Chinese Journal of Gastroenterology

摘　　要：胃食管反流病(GERD)系胃内容物反流入食管,引起不适症状和(或)并发症的一种疾病,食管下括约肌(LES)功能障碍和胃排空延迟引起胃内容物反流是GERD的主要发病机制。促动力药可通过改善胃食管动力治疗GERD,主要包括多巴胺受体拮抗剂、5-羟色胺(5-HT)_4受体激动剂、γ-氨基丁酸B型(GABAB)受体激动剂、5型代谢型谷氨酸受体(mGluR5)、选择性胆囊收缩素(CCK)-A受体拮抗剂、胃动素和5-HT_3部分激动剂。本文就促动力药治疗GERD的循证评价和进展作一概述。Gastroesophageal reflux disease （GERD） is a disorder manifested by reflux of stomach contents into the esophagus causing troublesome symptoms and/or complications. The main pathophysiological mechanism of GERD is dysfunction of lower esophageal sphincter （LES） and delayed gastric emptying, allowing stomach contents to seep into the esophagus. Prokinetic agents could relieve of reflux symptoms by improving esophageal and gastric motility, which include dopamine-receptor antagonist, 5-hydroxytryptamine （5-HT）4 receptor agonist, γ-aminobutyric acid type B （GABAB） receptor agonist, metabotropic glutamate receptor 5 （mGluR5）, selective cholecystokinin-A receptor antagonist, motihn and 5-HT3 receptor agonist. This article reviewed evidence-based evaluation and advances of prokinetic agents in the treatment of GERD.

关 键 词：促动力药物 胃食管反流 治疗 

分 类 号：R571[医药卫生—消化系统]